Seminars in Nephrology
Volume 29, Issue 2 , Pages 144-155 , March 2009

Diagnosis and Treatment of Osteoporosis in Chronic Renal Disease

  • Paul D. Miller, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Paul D. Miller, MD, Distinguished Clinical Professor of Medicine, University of Colorado Health Sciences Center, Medical Director, Colorado Center for Bone Research, Lakewood, CO 80227

References 

  1. Melton LJ. Epidemiology worldwide. Endocrinol Metab Clin North Am. 2003;32:1–13v
  2. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22:465–475
  3. Barrett-Connor E, Siris ES, Wehren LE, Miller PD, Abbott TA, Berger ML, et al. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res. 2005;20:185–194
  4. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis (Report of a WHO Study Group). World Health Organ Tech Rep Ser. 1994;843:1–129
  5. Miller PD, Bonnick SL. Clinical utilization of bone mass measurements for the assessment and management of osteoporosis in the adult population. In:  Favus M editors. Primer of metabolic bone diseases. Washington DC: American Society for Bone and Mineral Research; 1999;p. 152–159
  6. Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int. 2008;2:1–11
  7. Gal-Moscovici A, Sprague SM. Osteoporosis and chronic kidney disease. Semin Dial. 2007;20:423–430
  8. Parfitt AM, Drezner M, Glorieux F, Kanis J, Malluche H, Meunier P, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units (Report of the ASBMR Histomorphometry Nomenclature Committee). J Bone Miner Res. 1987;2:595–610
  9. Massry SG, Coburn JW. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Suppl 3):S10–S135
  10. Andress DL, Sherrard DJ. The osteodystrophy of chronic renal failure. In:  Schrier RW editors. Diseases of the kidney and urinary tract. Philadelphia: Lippincott Williams and Wilkins; 2003;p. 2735–2768
  11. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945–1953
  12. NIH Consensus Development Panel. Osteoporosis prevention diagnosis and therapy. JAMA. 2001;285:
  13. Baim S, Binkley N, Bilezikian JP, Kendler D, Hans D, Lewiecki EM, et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom. 2008;11:75–91
  14. Siris E, Miller P, Barrett-Connor E, Faulkner K, Wehren L, Abbott T, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA). JAMA. 2001;286:2815–2822
  15. Schuit SCE, Oei HH, Witteman JC, Geurts van Kessel CH, van Meurs JB, Nijhuis Rl, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34:195–202
  16. Bouxsein ML. Non-invasive measurements of bone strength: promise and peril. J Musculoskelet Neuronal Interact. 2004;4:404–405
  17. Seeman E. Bone quality: the material and structural basis of bone strength. J Bone Miner Metab. 2008;26:1–8
  18. Moe S, Drueke T Working Group of the Kidney Disease Improving Global Outcome. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease related mineral and bone disorders (CKD-MBD). Clin J Am Soc Nephrol. 2008;3:5124–5130
  19. Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58:396–399
  20. Ball AM, Gillen DL, Sherrard D, et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA. 2002;288:3014–3018
  21. Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006;70:1358–1366
  22. Stehman-Breen CO, Sherrard DJ, Alem AM, et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58:2200–2205
  23. Wehrli FW, Leonard MB, Saha PK, et al. Quantitative high-resolution magnetic resonance imaging reveals structural implications of renal osteodystrophy on trabecular and cortical bone. J Magn Reson Imaging. 2004;20:83–89
  24. Genant HK, Lang TF, Engelke K, et al. Advances in the noninvasive assessment of bone density, quality, and structure. Calcif Tissue Int. 1996;59(Suppl 1):S10–S15
  25. Roschger P, Paschalis EP, Fratzl P, Klaushofer K. Bone mineralization density distribution in health and disease. Bone. 2008;42:456–466
  26. Frost HM. Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res. 1969;3:211–237
  27. Hitt O, Jaworski ZF, Shimizu AG, Frost HM. Tissue-level bone formation rates in chronic renal failure, measured by means of tetracycline bone labeling. Can J Physiol Pharmacol. 1970;48:824–828
  28. Coen G. Adynamic bone disease: an update. J Nephrol. 2005;18:117–122
  29. Parfitt AM. Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens. 2003;12:387–403
  30. Brandenburg VM, Floege J. Adynamic bone disease-bone and beyond. Nephrol Dial Transplant. 2008;3:135–147
  31. Hruska KA, Saab G, Mathew S, Lund R. Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin Dial. 2007;20:309–315
  32. Miller PD, Hochberg MC, Wehren LE, Ross PD, Wasnich RD. How useful are measures of BMD and bone turnover?. Curr Med Res Opin. 2005;21:545–553
  33. Miller PD. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporosis Rep. 2005;3:103–110
  34. Chavassieux PM, Delmas PD. Bone remodeling: biochemical markers or bone biopsy?. J Bone Miner Res. 2006;21:178–179
  35. Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther. 2008;12:157–170
  36. Hochberg M, Greenspan S, Wasnich R, Miller P, Thompson D, Ross P. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586–1592
  37. Bouxsein ML, Delmas PD. Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res. 2008;23:1155–1167
  38. Chen P, Satterwhite JH, Licatta AA, Lewiecki EM, Sipos AA, Miskurski DM, et al. Early changes in biochemical markers of bone formation predict the BMD response with teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005;20:962–970
  39. Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, et al. Early responsiveness of women with osteoporosis to teriparatide following therapy with alendronate or risedronate. J Clin Endocrinol Metab. 2008;93:3785–3793
  40. Miller PD, Lerma EV. Renal bone diseases. In:  Kleerekoper M,  Siris E,  McClung M editor. the bone and mineral manual—a practical guide. 2nd ed.. Burlington, MA: Elsevier Academic Press; 2005;
  41. Miller PD. Is there a role for bisphosphonates in patients with stage 5 chronic kidney disease?. Semin Dial. 2007;20:191–197
  42. Miller PD. Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In:  Marcus R,  Feldman D,  Nelson DA,  Rosen CJ editor. Osteoporosis. 3rd ed.. San Diego, CA: Elsevier Academic Press; 2007;p. 1725–1736
  43. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis Int. 2008;
  44. Dawson-Hughes B, Bischoff-Ferrari HA. Therapy of osteoporosis with calcium and vitamin D. J Bone Miner Res. 2007;22(Suppl 2):V59–V63
  45. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18:1033–1046
  46. Dawson-Hughes B, Tosteson AN, Melton LJ, Baim S, Favus M, Khossla S, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19:449–458
  47. Eisman JA, Civetelli R, Adami S, Czerwinski E, Recknor C, Prince R, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol. 2008;35:488–497
  48. Black DM, Delmas PD, Eastell RR, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–1822
  49. Lewiecki EM, Miller PD. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf. 2007;6:663–672
  50. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008;
  51. Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Messenbrink P, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int. 2008;74:641–648
  52. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JA, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–1441
  53. Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH. Teriparatide in postmenopausal women with osteoporosis and impaired renal function. Osteoporosis Int. 2007;18:59–68
  54. Miller PD, Roux C, Boonen S, Barton I, Dunlap L, Burgio D. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005;20:2015–2115
  55. Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007;22:503–508
  56. Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol. 2008;19:1430–1438
  57. Miller PD. The role of bone biopsy in chronic renal failure. Clin J Am Soc Nephrol. 2008;3:5140–5151
  58. Ferreira MA. Diagnosis of renal osteodystrophy: when and how to use biochemical markers and non-invasive methods; when bone biopsy is needed. Nephrol Dial Transplant. 2000;15(Suppl 5):8–14
  59. Trueba D, Sawaya BP, Mawad H, Malluche HH. Bone biopsy: indications, techniques, and complications. Semin Dial. 2003;16:341–345
  60. Miller PD, Shane E. Management of transplantation renal bone disease: Interplay of bone mineral density and decision regarding bisphosphonate use. In:  Weir MR editors. Medical management of kidney transplantation. Baltimore: Lippincott Williams and Wilkins; 2005;p. 359–375

PII: S0270-9295(09)00008-4

doi: 10.1016/j.semnephrol.2009.01.007

Seminars in Nephrology
Volume 29, Issue 2 , Pages 144-155 , March 2009

Article Tools

* Image Usage & Resolution